Page 108 - 2020年20期

[ 3 ] 中华医学会糖尿病学分会.中国 2 型糖尿病防治指南： 2015，6（1）：75-84.
2017年版[J].中华糖尿病杂志，2018，10（1）：4-67. [18] GUIMARES C，MARRA CA，COLLEY L，et al. A valua-
[ 4 ] 李雪贝，张良，冷远景，等.当代2型糖尿病临床治疗药物 tion of patients’willingness-to-pay for insulin delivery in
的研究进展[J].中国医院药学杂志，2016，36（20）：1824- diabetes[J]. Int J Technol Assess，2009，25（3）：359-366.
1828. [19] MOHAMED AF，ZHANG J，JOHNSON FR，et al. Avoi-
[ 5 ] PA S. A note on measurement of utility[J]. Rev Econ Stud， dance of weight gain is important for oral type 2 diabetes
1937，4（2）：155-161. treatments in Sweden and Germany：patient preferen-
[ 6 ] BRIDGES J，ONUKWUGHA E，JOHNSON FR，et al. Pa- ces[J]. Diabetes Metab，2013，39（5）：397-403.
tient preferencemethods：a patient centered evaluation par- [20] JENDLE J，TORFFVIT O，RIDDERSTRALE M，et al.
adigm[J]. ISPOR Connections，2007，13（1）：4-7. Willingness to pay for health improvements associated
[ 7 ] BRIDGES JF，HAUBER AB，MARSHALL D，et al. Con- with anti-diabetes treatments for people with type 2 diabe-
joint analysis applications in health：a checklist：a report tes[J]. Curr Med Res Opin，2010，26（4）：917-923.
of the ISPOR good research practices for conjoint analysis [21] HAUBER AB，JOHNSON FR，SAURIOL L，et al. Risk-
task force[J]. Value Health，2011，14（4）：403-413. ing health to avoid injections：preferences of Canadians
[ 8 ] JEON Y，HERRIGES JA. Convergent validity of contin- with type 2 diabetes[J]. Diabetes Care，2005，28（9）：
gent behavior responses in models of recreation de- 2243-2245.
mand[J]. Environ Resour Econ，2010，45（2）：223-250. [22] QIN L，CHEN S，FLOOD E，et al. Glucagon-like peptide-1
[ 9 ] RYAN M，SCOTT DA，REEVES C，et al. Eliciting public receptor agonist treatment attributes important to injec-
preferences for healthcare：a systematic review of tech- tion-experienced patients with type 2 diabetes mellitus：a
niques[J]. Health Technol Assess，2001，5（5）：1-186. preference study in Germany and the United Kingdom[J].
[10] 胡婉侠，徐文华，徐建光，等.我国卫生领域离散选择实验 Diabetes Ther，2017，8（2）：335-353.
应用研究的文献计量分析[J].南京医科大学学报（社会 [23] MARCHESINI G，PASQUALETTI P，ANICHINI R，
科学版），2020，20（2）：157-161. et al. Patient preferences for treatment in type 2 diabetes：
[11] LOUVIERE JJ，LANCSAR E. Choice experiments in the Italian discrete-choice experiment analysis[J]. Acta Di-
health：the good，the bad，the ugly and toward a brighter abetol，2019，56（3）：289-299.
future[J]. Health Econ Policy：Ⅰ，2009，4（4）：527-546. [24] LLOYD A，NAFEES B，BARNETT AH，et al. Willing-
[12] DE BEKKER-GROB EW，RYAN M，GERARD K. Dis- ness to pay for improvements in chronic long-acting insu-
crete choice experiments in health economics：a review of lin therapy in individuals with type 1 or type 2 diabetes
the literature[J]. Health Econ，2012，21（2）：145-172. mellitus[J]. Clin Ther，2011，33（9）：1258-1267.
[13] MANDEVILLE KL，LAGARDE M，HANSON K. The [25] MÜHLBACHER A，BETHGE S. What matters in type 2
use of discrete choice experiments to inform health work- diabetes mellitus oral treatment：a discrete choice experi-
force policy：a systematic review[J]. BMC Health Serv ment to evaluate patient preferences[J]. Eur J Health
Res，2014. DOI：10.1186/1472-6963-14-367. Econ，2016，17（9）：1125-1140.
[14] POLSTER M，ZANUTTO E，MCDONALD S，et al. A [26] FIFER S，ROSE J，HAMROSI KK，et al. Valuing injec-
comparison of preferences for two GLP-1 products：lira- tion frequency and other attributes of type 2 diabetes treat-
glutide and exenatide：for the treatment of type 2 diabe- ments in Australia：a discrete choice experiment[J]. BMC
tes[J]. J Med Econ，2010，13（4）：655-661. Health Serv Res，2018. DOI：10.1186/s12913-018- 3484-0.
[15] GUIMARAES C，MARRA C，GILL S，et al. A discrete [27] HAUBER AB，MOHAMED AF，JOHNSON FR，et al.
choice experiment evaluation of patients’preferences for Treatment preferences and medication adherence of peo-
different risk，benefit，and delivery attributes of insulin ple with type 2 diabetes using oral glucose-lowering
therapy for diabetes management[J]. Patient Prefer Adher， agents[J]. Diabet Med，2009，26（4）：416-424.
2010. DOI：10.2147/PPA.S14217. [28] DE VRIES ST，DE VRIES FM，DEKKER T，et al. The
[16] CASCIANO R，MALANGONE E，RAMACHANERAN role of patients’age on their preferences for choosing ad-
A，et al. A quantitative assessment of patient barriers to in- ditional blood pressure-lowering drugs：a discrete choice
sulin[J]. Int J Clin Pract，2011，65（4）：408-414. experiment in patients with diabetes[J]. PLoS One，2015.
[17] HAUBER AB，TUNCELI K，YANG JC，et al. A survey of DOI：10.1371/journal.pone.0139755.
patient preferences for oral antihyperglycemic therapy in [29] GUIMARAES C，MARRA CA，COLLRY L，et al. Socio-
patients with type 2 diabetes mellitus[J]. Diabetes Ther， economic differences in preferences and willingness-to-

·2530 · China Pharmacy 2020 Vol. 31 No. 20 中国药房 2020年第31卷第20期